Betahistine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Betahistine: From Meniere Disease to Restless Legs Syndrome
One-Sentence Summary
Betahistine is an oral histamine-analogue tablet, originally used to treat Meniere disease and endolymphatic hydrops. The TxGNN model's top-ranked new prediction is restless legs syndrome, but it rests on model output alone, with 0 clinical trials and 0 publications supporting it. The better-supported predictions are vestibular conditions close to the original indication, such as peripheral vertigo (20 publications) and vertigo, benign recurrent, 2 (about 20 publications). These are largely confirmations of existing use, not new repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Meniere disease, endolymphatic hydrops (the Singapore licence records contain no indication text) |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 98.51% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. From the literature, betahistine is a weak histamine H1 receptor agonist and a more potent H3 receptor antagonist/inverse agonist. This raises histamine turnover and central histaminergic tone. In the inner ear it is thought to improve cochlear and labyrinthine microcirculation, and in the brain it promotes vestibular compensation.
For restless legs syndrome, the link is plausible but unsupported. It would run through histaminergic and dopaminergic modulation in the central nervous system. No trials or publications were found for this pairing, so the prediction should be treated as a hypothesis.
The other predictions fall into three groups:
- Same disease family as the original indication: active cochleovestibular, vestibular and cochlear Meniere disease. The supporting evidence is indirect, through the approved Meniere indication and sibling entries.
- Closely related vestibular conditions: peripheral vertigo and benign recurrent vertigo, which have the largest bodies of literature.
- Weak or likely artifact predictions: otosclerosis, age-related hearing impairment, and the two hyperinsulinism conditions. No plausible mechanism links betahistine to Kir6.2/KATP channel deficiency.
Clinical Trial Evidence
Currently no related clinical trials registered for any of the top 10 predicted indications.
Literature Evidence
There is no literature for restless legs syndrome. The table below shows the strongest evidence for the closest-related predictions, peripheral vertigo and the vestibular and cochlear Meniere entries.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26797774 | 2016 | RCT (BEMED) | BMJ | Long-term, multicentre, double-blind, placebo-controlled, dose-defining trial in Meniere disease. A 2017 commentary (PMID 28850992) notes that betahistine did not reduce vertigo attacks significantly better than placebo. |
| 36827524 | 2023 | Systematic review | Cochrane Database Syst Rev | Systemic pharmacological interventions for Meniere disease, including betahistine, diuretics, antivirals and corticosteroids |
| 27327415 | 2016 | Systematic review | Cochrane Database Syst Rev | Betahistine versus placebo for vertigo symptoms of various causes |
| 23778722 | 2014 | Meta-analysis | Eur Arch Otorhinolaryngol | 12 double-blind placebo-controlled studies in Meniere disease and vestibular vertigo |
| 12582782 | 2003 | RCT | Eur Arch Otorhinolaryngol | Betahistine versus placebo in 144 patients with Meniere disease or paroxysmal positional vertigo |
| 6363584 | 1984 | RCT (crossover) | J Laryngol Otol | Betahistine 12 mg three times daily versus placebo in 24 patients with peripheral vestibular vertigo |
| 20940335 | 2011 | RCT | J Clin Pharmacol | Betahistine improved recovery of static symptoms after unilateral vestibular neurotomy in Meniere patients |
| 26245698 | 2015 | Review | Acta Otolaryngol | Betahistine reported as effective and safe in Meniere disease, BPPV and vestibular neuronitis |
| 26139562 | 2015 | Preclinical | Audiol Neurootol | H3 heteroreceptors as a possible mediator of the betahistine-induced rise in cochlear blood flow |
| 28818391 | 2017 | Preclinical | Life Sci | Roles of capillary pericytes and precapillary arterioles in betahistine's vascular mechanism (guinea pig) |
Overall, the evidence for Meniere disease is described in the literature as mixed. Some small controlled studies and meta-analyses favour betahistine, while the large BEMED trial did not show a significant benefit over placebo.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11365P | BETASERC TABLETS 16 mg | Tablet | Not stated in the data |
| SIN12235P | BETASERC 24 TABLET 24 mg | Tablet | Not stated in the data |
| SIN16812P | GP-BETAHISTINE TABLETS 24MG | Tablet | Not stated in the data |
| SIN03047P | MERISLON TABLET 6 mg | Tablet | Not stated in the data |
All four authorizations are valid single-ingredient oral tablets.
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, restless legs syndrome, has no supporting trials or literature, so it is a model output only (L5). The better-evidenced predictions, such as peripheral vertigo and benign recurrent vertigo, are mostly on-label or near-label vestibular uses (L3). Those could proceed with guardrails, but they are confirmation of existing use and not true repurposing. The mixed efficacy evidence, including the BEMED trial, argues for caution.
To proceed, the following is needed:
- A literature search and mechanistic review on histaminergic/dopaminergic links to restless legs syndrome, followed by a pilot study if the link holds up
- The Singapore package insert, to obtain approved indications, warnings and contraindications
- Mechanism of action data to support the mechanistic analysis
- For the vestibular predictions, a focused appraisal of the BEMED trial against the positive meta-analyses to settle the efficacy question
- Dismissal of the Kir6.2 and familial hyperinsulinism predictions unless a plausible mechanism emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.